Veradermics (MANE) Liabilities and Shareholders Equity (2024 - 2026)

Veradermics' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $397.4 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $397.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $605.5 million (changed N/A YoY) and the FY2025 annual result came in at $152.6 million, up 174.82% from the prior year.
• Liabilities and Shareholders Equity was $397.4 million for Q1 2026 at Veradermics, up from $152.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $397.4 million in Q1 2026 and bottomed at $55.5 million in Q4 2024.
• A 3-year average of $201.8 million and a median of $152.6 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 174.82% in 2025, while the deepest fall reached 174.82% in 2025.
• Veradermics' Liabilities and Shareholders Equity stood at $55.5 million in 2024, then surged by 174.82% to $152.6 million in 2025, then soared by 160.36% to $397.4 million in 2026.
• Business Quant data shows MANE's Liabilities and Shareholders Equity at $397.4 million in Q1 2026, $152.6 million in Q4 2025, and $55.5 million in Q4 2024.